Showing results (371-380 of 427) with videos related to
Sort By:
Pageof 43
Leukemia Research|January 22, 2005
Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatmentRoberto Latagliata, Latagliata Roberto, Massimo Breccia, et al.Annals of Hematology|January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapyFrancesca Palandri, Filippo Branzanti, Erika Morsia, et al.Neoplasia (New York, N.Y.)|September 24, 2016
Frontline Dasatinib Treatment in a "Real-Life" Cohort of Patients Older than 65 Years with Chronic Myeloid LeukemiaRoberto Latagliata, Fabio Stagno, Mario Annunziata, et al.Leukemia|November 18, 2025
Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpointFausto Castagnetti, Massimo Breccia, Elisabetta Abruzzese, et al.Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.Leukemia Research|August 19, 2015
Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patientsMassimo Breccia, Fabio Efficace, Simona Sica, et al.British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.Annals of Hematology|July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study designValerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.Leukemia|March 23, 2023
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy resultsMichael J Mauro, Timothy P Hughes, Dong-Wook Kim, et al.Pageof 43